• Vector Science and Therapeutics welcomed U.S. Health Secretary Robert F. Kennedy Jr.'s call for a regulated peptide marketplace.
• The company said its prescription peptides already meet the manufacturing, independent testing and physician oversight standards Kennedy described.
• Management expects a regulated market to shift demand from gray-market peptides toward suppliers that can document product quality.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vector Science and Therapeutics Corp. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610221241PR_NEWS_USPR_____LA79159) on October 22, 2026, and is solely responsible for the information contained therein.